1. In adrenal steroidogenesis, two distinct events occur at the mitochondria: cholesterol must first cross from the outer to the inner mitochondrial membrane, and it must then be enzymatically converted to pregnenolone. Which of the following correctly distinguishes the molecule responsible for the transport event from the one responsible for the enzymatic conversion?
A) StAR protein performs the enzymatic cleavage of the cholesterol side chain to form pregnenolone, while CYP11A1 transports cholesterol across the mitochondrial membranes
B) Both the transport and the enzymatic conversion are performed by CYP11A1, with StAR protein serving only as a regulatory cofactor that has no independent transport or catalytic function
C) StAR (steroidogenic acute regulatory) protein mediates cholesterol transport from the outer to the inner mitochondrial membrane, while CYP11A1 (cholesterol side-chain cleavage enzyme) catalyzes the conversion of cholesterol to pregnenolone at the inner membrane
D) StAR protein transports cholesterol across the membranes, while 3β-HSD (3 beta-hydroxysteroid dehydrogenase) catalyzes the conversion of cholesterol to pregnenolone in the same mitochondrial compartment
E) CYP11A1 transports cholesterol to the inner mitochondrial membrane and also converts it to pregnenolone, while StAR protein acts downstream to convert pregnenolone to progesterone
ANSWER: C
Rationale:
Two mechanistically distinct events must be distinguished. StAR (steroidogenic acute regulatory) protein mediates the transport of cholesterol from the outer to the inner mitochondrial membrane — this is the rate-limiting step of steroidogenesis and is acutely upregulated by ACTH via cAMP/PKA signaling. Once cholesterol reaches the inner mitochondrial membrane, CYP11A1 (cholesterol side-chain cleavage enzyme, also called P450scc) catalyzes its conversion to pregnenolone — the committed enzymatic step of steroid synthesis. The transport function (StAR) and the catalytic function (CYP11A1) are performed by separate molecules acting in sequence.
Option A: Option A is incorrect because it reverses the two roles. StAR is the transport protein, not the enzyme that cleaves the cholesterol side chain; CYP11A1 is the enzyme that cleaves the side chain, not the transporter. The reversal inverts the actual division of labor between the two molecules.
Option B: Option B is incorrect because StAR is not merely a regulatory cofactor — it performs the physical transport of cholesterol across the mitochondrial membranes, an indispensable function demonstrated by congenital lipoid adrenal hyperplasia, in which StAR mutations cause near-total loss of steroid synthesis. CYP11A1 does not perform the transport step.
Option D: Option D is incorrect because while it correctly identifies StAR as the transporter, it misidentifies the enzyme that converts cholesterol to pregnenolone. That conversion is catalyzed by CYP11A1, not 3β-HSD (3 beta-hydroxysteroid dehydrogenase). 3β-HSD acts later in the pathway, converting pregnenolone to progesterone in the delta-4 pathway.
Option E: Option E is incorrect because CYP11A1 does not transport cholesterol — that is the function of StAR. CYP11A1 catalyzes only the conversion of cholesterol to pregnenolone. Furthermore, StAR does not convert pregnenolone to progesterone; that reaction is catalyzed by 3β-HSD. The option misassigns both the transport and the downstream conversion.
2. The terms "rate-limiting step" and "committed step" describe two different control points in adrenal steroidogenesis and should not be conflated. Which of the following correctly identifies the committed step of steroid synthesis and distinguishes it from the rate-limiting step?
A) The committed step is the CYP11A1-catalyzed conversion of cholesterol to pregnenolone, which channels the substrate irreversibly into the steroidogenic pathway; the rate-limiting step is the StAR-mediated transport of cholesterol to the inner mitochondrial membrane that determines the overall rate of synthesis
B) The committed step and the rate-limiting step are the same event — the StAR-mediated transport of cholesterol — because the transport step both commits the substrate and limits the rate, making the distinction between the two terms purely semantic
C) The committed step is the CYP21A2-catalyzed conversion of 17-OHP to 11-deoxycortisol, which commits the intermediate to cortisol synthesis; the rate-limiting step is the CYP11A1-catalyzed cleavage of the cholesterol side chain
D) The committed step is the CYP17A1-catalyzed 17-hydroxylation of pregnenolone, which commits the pathway toward cortisol; the rate-limiting step is the conversion of cholesterol to pregnenolone by CYP11A1
E) The committed step is the 3β-HSD-catalyzed conversion of pregnenolone to progesterone; the rate-limiting step is the CYP11B1-catalyzed conversion of 11-deoxycortisol to cortisol in the final mitochondrial reaction
ANSWER: A
Rationale:
The committed step and the rate-limiting step are distinct control points. The committed step is the CYP11A1 (cholesterol side-chain cleavage enzyme)-catalyzed conversion of cholesterol to pregnenolone: once cholesterol is cleaved to pregnenolone, the molecule is irreversibly channeled into the steroidogenic pathway. The rate-limiting step, by contrast, is the StAR (steroidogenic acute regulatory) protein-mediated transport of cholesterol from the outer to the inner mitochondrial membrane — this transport determines the overall rate of steroid synthesis and is the point at which acute ACTH-mediated regulation acts. Distinguishing these two concepts is foundational: the rate-limiting step controls how fast substrate enters the pathway, while the committed step is the first irreversible enzymatic commitment.
Option B: Option B is incorrect because the committed step and rate-limiting step are not the same event, and the distinction is not merely semantic. StAR-mediated transport is the rate-limiting step; CYP11A1-catalyzed cleavage of cholesterol to pregnenolone is the committed enzymatic step. These are sequential and mechanistically separate — one is a transport event, the other an enzymatic conversion.
Option C: Option C is incorrect because the committed step of overall steroidogenesis is the CYP11A1-catalyzed conversion of cholesterol to pregnenolone, not the CYP21A2-catalyzed conversion of 17-OHP to 11-deoxycortisol. The CYP21A2 step commits an intermediate toward cortisol within the glucocorticoid branch but is not the committed step of steroidogenesis as a whole. The option also misidentifies CYP11A1 cleavage as rate-limiting when it is the committed step.
Option D: Option D is incorrect because the committed step of steroidogenesis is the conversion of cholesterol to pregnenolone by CYP11A1, not the 17-hydroxylation of pregnenolone by CYP17A1. CYP17A1 activity directs intermediates toward cortisol and androgens versus mineralocorticoids, but it acts downstream of the committed step. The option incorrectly labels the CYP11A1 reaction as merely rate-limiting.
Option E: Option E is incorrect because neither identification is correct. The committed step is the CYP11A1 conversion of cholesterol to pregnenolone, not the 3β-HSD conversion of pregnenolone to progesterone. The rate-limiting step is StAR-mediated cholesterol transport, not the CYP11B1-catalyzed final hydroxylation to cortisol. The option misassigns both control points to downstream reactions.
3. CYP17A1 is unusual among steroidogenic enzymes in that it possesses two distinct catalytic activities. Correctly distinguishing these two activities — and distinguishing CYP17A1 from CYP21A2 — is essential to understanding why the zona reticularis produces adrenal androgens. Which of the following statements is correct?
A) CYP17A1 possesses only hydroxylase activity; the lyase activity required to form DHEA is supplied by a separate enzyme, CYP21A2, which acts on 17-hydroxypregnenolone in the zona reticularis
B) CYP17A1 and CYP21A2 both catalyze 17-hydroxylation reactions; the difference is that CYP17A1 acts in the zona fasciculata and CYP21A2 acts in the zona reticularis, producing cortisol and androgens respectively
C) CYP17A1 possesses only lyase activity, cleaving the side chain of 17-hydroxyprogesterone to form androstenedione directly; the 17-hydroxylation step is performed by CYP21A2 upstream
D) CYP17A1 possesses both 17-hydroxylase activity (adding a hydroxyl group at the 17 position, directing intermediates toward cortisol) and 17,20-lyase activity (cleaving the C17–C20 bond to form DHEA and androstenedione, directing intermediates toward androgens); CYP21A2 is a separate enzyme that performs 21-hydroxylation, converting 17-OHP to 11-deoxycortisol
E) CYP17A1 catalyzes the 21-hydroxylation of progesterone while CYP21A2 catalyzes the 17-hydroxylation step; the two enzymes have overlapping substrate specificity and can substitute for one another when either is deficient
ANSWER: D
Rationale:
CYP17A1 (cytochrome P450 17A1) is a single enzyme with two distinct catalytic activities. Its 17-hydroxylase activity adds a hydroxyl group at the 17 position of pregnenolone or progesterone, directing intermediates toward cortisol synthesis (via 17-OHP). Its 17,20-lyase activity cleaves the C17–C20 carbon bond, converting 17-hydroxypregnenolone to DHEA (dehydroepiandrosterone) and 17-OHP to androstenedione, thereby directing intermediates toward androgen synthesis. The balance between these two activities — high lyase activity in the zona reticularis — explains why that zone produces adrenal androgens. CYP21A2 (21-hydroxylase) is an entirely separate enzyme that performs 21-hydroxylation, converting 17-OHP to 11-deoxycortisol in the glucocorticoid pathway. Distinguishing the dual-function CYP17A1 from the single-function CYP21A2 is essential to understanding adrenal androgen production and the biochemistry of congenital adrenal hyperplasia.
Option A: Option A is incorrect because CYP17A1 possesses both hydroxylase and lyase activities — the lyase activity is intrinsic to CYP17A1, not supplied by CYP21A2. CYP21A2 performs 21-hydroxylation and has no lyase activity and no role in DHEA formation.
Option B: Option B is incorrect because CYP17A1 and CYP21A2 do not both catalyze 17-hydroxylation. CYP17A1 performs 17-hydroxylation (and 17,20-lyase activity); CYP21A2 performs 21-hydroxylation. They catalyze different reactions at different carbon positions, not the same reaction in different zones.
Option C: Option C is incorrect because CYP17A1 possesses both hydroxylase and lyase activities, not lyase activity alone. Moreover, the 17-hydroxylation step is performed by CYP17A1 itself, not by CYP21A2. CYP21A2 performs 21-hydroxylation, an entirely different reaction that does not precede CYP17A1 lyase activity.
Option E: Option E is incorrect because it reverses the catalytic functions of the two enzymes and falsely asserts overlapping specificity. CYP17A1 performs 17-hydroxylation and 17,20-lyase reactions, not 21-hydroxylation; CYP21A2 performs 21-hydroxylation, not 17-hydroxylation. The two enzymes have distinct, non-overlapping functions and cannot substitute for one another — which is precisely why deficiency of either produces a characteristic and non-redundant biochemical phenotype.
4. The two principal regulatory inputs to the adrenal cortex — ACTH and angiotensin II — act on different zones through different receptors and second-messenger systems. Which of the following correctly distinguishes the receptor and signaling mechanism for ACTH-driven cortisol synthesis from that for angiotensin II-driven aldosterone synthesis?
A) ACTH acts on AT1 (angiotensin type 1) receptors in the zona fasciculata through a calcium-dependent mechanism, while angiotensin II acts on MC2R (melanocortin 2 receptor) in the zona glomerulosa through a cAMP-dependent mechanism
B) ACTH acts on MC2R (melanocortin 2 receptor), a Gs-coupled G protein-coupled receptor on zona fasciculata cells, raising cAMP and activating PKA to drive cortisol synthesis; angiotensin II acts on AT1 (angiotensin type 1) receptors on zona glomerulosa cells through calcium-dependent signaling to drive aldosterone synthesis
C) Both ACTH and angiotensin II act on MC2R (melanocortin 2 receptor), but ACTH couples it to Gs and cAMP while angiotensin II couples the same receptor to Gq and calcium signaling, depending on which zone the receptor is expressed in
D) ACTH acts on MC2R in the zona glomerulosa to drive aldosterone synthesis through cAMP, while angiotensin II acts on AT1 receptors in the zona fasciculata to drive cortisol synthesis through calcium signaling
E) ACTH and angiotensin II both signal through cAMP and PKA; the difference is that ACTH acts on the zona fasciculata to produce cortisol while angiotensin II acts on the same cells to enhance the same cAMP signal, amplifying cortisol output rather than producing aldosterone
ANSWER: B
Rationale:
ACTH and angiotensin II regulate different adrenal zones through different receptors and second-messenger systems. ACTH (adrenocorticotropic hormone) binds MC2R (melanocortin 2 receptor), a Gs-coupled G protein-coupled receptor expressed on zona fasciculata (and reticularis) cells; activation raises intracellular cAMP (cyclic adenosine monophosphate), activates PKA (protein kinase A), and drives cortisol synthesis by phosphorylating StAR and increasing cholesterol transport. Angiotensin II acts on AT1 (angiotensin type 1) receptors on zona glomerulosa cells through calcium-dependent signaling (along with elevated serum potassium directly depolarizing glomerulosa cells), increasing CYP11B2 expression and driving aldosterone synthesis. The zone-specific receptor expression and signaling pathways explain why ACTH primarily controls cortisol while angiotensin II and potassium primarily control aldosterone.
Option A: Option A is incorrect because it reverses the receptor assignments. ACTH acts on MC2R (not AT1 receptors), and angiotensin II acts on AT1 receptors (not MC2R). The signaling mechanisms are also reversed: ACTH/MC2R uses cAMP, while angiotensin II/AT1 uses calcium-dependent signaling.
Option C: Option C is incorrect because ACTH and angiotensin II do not act on the same receptor. ACTH acts on MC2R; angiotensin II acts on AT1 receptors. These are distinct receptors expressed in different zones, not a single receptor coupled to different G proteins depending on location.
Option D: Option D is incorrect because it reverses both the zones and the products. ACTH acts on the zona fasciculata to drive cortisol (not the zona glomerulosa to drive aldosterone), and angiotensin II acts on the zona glomerulosa to drive aldosterone (not the zona fasciculata to drive cortisol). The receptor-to-zone and receptor-to-product mappings are both inverted.
Option E: Option E is incorrect because ACTH and angiotensin II do not both signal through cAMP and PKA. ACTH/MC2R signals through cAMP/PKA, whereas angiotensin II/AT1 signals through calcium-dependent pathways. Furthermore, angiotensin II drives aldosterone synthesis in the zona glomerulosa — it does not amplify cortisol output in the zona fasciculata.
5. Two genomic modes of glucocorticoid receptor action are distinguished by whether the receptor binds DNA directly and whether it acts as a dimer or a monomer. Correctly distinguishing transactivation from tethered transrepression is foundational to understanding the therapeutic-versus-adverse-effect profile of glucocorticoids. Which of the following correctly characterizes these two modes?
A) Both transactivation and transrepression require GR-alpha to bind GRE sequences directly as a homodimer; the two modes differ only in whether the recruited cofactor is a coactivator or a corepressor
B) Transactivation occurs when a GR-alpha monomer tethers to NF-κB without binding DNA, while transrepression occurs when a GR-alpha homodimer binds GRE sequences directly and recruits corepressors
C) Transactivation and transrepression both occur through GR-alpha monomers that never bind DNA; the distinction is whether the monomer tethers to a coactivator or a corepressor protein in the nucleus
D) Transactivation occurs through non-genomic membrane signaling that requires no DNA binding, while transrepression is the only genomic mode and requires GR-alpha homodimer binding to GRE sequences
E) Transactivation occurs when a GR-alpha homodimer binds GRE (glucocorticoid response element) sequences directly and recruits coactivators to drive transcription, whereas tethered transrepression occurs when a GR-alpha monomer physically binds a pro-inflammatory transcription factor such as NF-κB without binding DNA itself, blocking that factor's activity
ANSWER: E
Rationale:
The two genomic modes of glucocorticoid receptor action are distinguished by DNA binding and oligomerization state. In transactivation, a ligand-activated GR-alpha homodimer binds directly to GRE (glucocorticoid response element) sequences in target gene promoters and recruits coactivator complexes (such as CBP/p300 and SRC-1) to enhance transcription; this drives expression of metabolic genes responsible for many adverse effects. In tethered transrepression, a GR-alpha monomer does not bind DNA directly but instead physically interacts with pro-inflammatory transcription factors — principally NF-κB (nuclear factor kappa B) and AP-1 (activator protein 1) — preventing them from engaging their coactivators and thereby blocking transcription of pro-inflammatory genes; this is the principal mechanism of the anti-inflammatory effect. The dimer-on-DNA versus monomer-tethered distinction is the conceptual foundation for understanding why separating these two modes has been a long-standing drug-development goal.
Option A: Option A is incorrect because transrepression does not require GR-alpha to bind GRE sequences directly. Transactivation involves homodimer binding to GRE DNA; tethered transrepression involves a monomer binding a transcription factor without direct DNA contact. The two modes differ fundamentally in DNA binding, not merely in cofactor type.
Option B: Option B is incorrect because it reverses the two modes. Transactivation is the homodimer-on-GRE mode that recruits coactivators; tethered transrepression is the monomer-tethered-to-NF-κB mode that occurs without direct DNA binding. The option swaps the mechanisms.
Option C: Option C is incorrect because transactivation does involve direct DNA binding — a GR-alpha homodimer binds GRE sequences. It is not true that both modes occur through monomers that never bind DNA; only tethered transrepression fits that description. Transactivation requires homodimer binding to DNA.
Option D: Option D is incorrect because transactivation is a genomic mode requiring homodimer binding to GRE sequences, not a non-genomic membrane-signaling mechanism. Both transactivation and tethered transrepression are genomic modes; non-genomic membrane signaling is a separate, rapid mechanism distinct from both. The option mischaracterizes transactivation as non-genomic.
6. Glucocorticoids repress gene transcription through two distinct mechanisms that must not be conflated: repression at negative glucocorticoid response elements (nGREs) and tethered transrepression of pro-inflammatory transcription factors. Which of the following correctly distinguishes these two repressive mechanisms and their principal physiological roles?
A) nGRE-mediated repression and tethered transrepression are two names for the same mechanism — GR-alpha binding to NF-κB — and both serve primarily to suppress HPA axis feedback through repression of the POMC gene
B) nGRE-mediated repression suppresses pro-inflammatory genes such as COX-2 and the interleukins, while tethered transrepression suppresses the POMC and CRH genes that mediate HPA axis feedback
C) nGRE-mediated repression occurs when GR-alpha binds directly to negative glucocorticoid response element DNA sequences in promoters such as the POMC gene (pituitary) and CRH gene (hypothalamus), repressing transcription and contributing to HPA axis feedback; tethered transrepression occurs when a GR-alpha monomer binds a pro-inflammatory transcription factor such as NF-κB without binding DNA, suppressing inflammatory gene transcription
D) Both nGRE-mediated repression and tethered transrepression require GR-alpha to tether to a transcription factor without binding DNA; the only difference is the identity of the tethered factor — POMC in one case and NF-κB in the other
E) nGRE-mediated repression is a non-genomic mechanism operating within minutes, while tethered transrepression is a genomic mechanism requiring 30 to 60 minutes; both act on the POMC gene to suppress ACTH secretion
ANSWER: C
Rationale:
Two distinct repressive mechanisms must be distinguished. nGRE (negative glucocorticoid response element)-mediated repression occurs when GR-alpha binds directly to specific negative response element DNA sequences in target gene promoters — notably the POMC (pro-opiomelanocortin) gene in the pituitary and the CRH (corticotropin-releasing hormone) gene in the hypothalamus — directly repressing transcription of these precursor peptides and thereby contributing to HPA axis negative feedback. Tethered transrepression, by contrast, occurs when a GR-alpha monomer physically binds a pro-inflammatory transcription factor such as NF-κB (nuclear factor kappa B) or AP-1 (activator protein 1) without binding DNA itself, blocking transcription of pro-inflammatory genes such as COX-2, iNOS, and the interleukins. The first mechanism involves direct DNA binding and mediates feedback; the second involves protein-protein tethering and mediates anti-inflammatory effects.
Option A: Option A is incorrect because nGRE-mediated repression and tethered transrepression are not the same mechanism. nGRE repression involves direct GR-alpha binding to DNA; tethered transrepression involves GR-alpha binding to a transcription factor without DNA contact. They also serve different roles — feedback versus anti-inflammatory suppression.
Option B: Option B is incorrect because it reverses the two mechanisms' targets. nGRE-mediated repression acts on the POMC and CRH genes for feedback, while tethered transrepression suppresses pro-inflammatory genes such as COX-2 and the interleukins. The option swaps the gene targets.
Option D: Option D is incorrect because nGRE-mediated repression does require direct DNA binding by GR-alpha — it binds the nGRE sequence itself. It is not a tethering mechanism. Only tethered transrepression occurs without direct DNA binding. The two mechanisms differ in DNA binding, not merely in the identity of a tethered factor.
Option E: Option E is incorrect because nGRE-mediated repression is a genomic mechanism requiring DNA binding and transcriptional changes, not a non-genomic mechanism operating within minutes. Furthermore, the two mechanisms do not both act on the POMC gene: tethered transrepression acts on pro-inflammatory genes, while nGRE repression acts on POMC and CRH. The timing and target assignments are both incorrect.
7. The glucocorticoid receptor gene produces two principal isoforms, GR-alpha and GR-beta, that differ critically in their ligand-binding domains. Which of the following correctly distinguishes the two isoforms and the functional consequence of that difference?
A) GR-alpha is the principal functional isoform that binds glucocorticoids and mediates genomic actions; GR-beta has an altered ligand-binding domain that does not bind glucocorticoids and acts as a dominant-negative inhibitor of GR-alpha, with elevated GR-beta expression associated with glucocorticoid resistance
B) GR-alpha does not bind glucocorticoids and serves as a dominant-negative regulator, while GR-beta is the functional isoform that binds ligand and mediates all genomic glucocorticoid actions
C) GR-alpha and GR-beta both bind glucocorticoids with equal affinity; they differ only in tissue distribution, with GR-alpha expressed in immune cells and GR-beta expressed in hepatic and muscle tissue
D) GR-alpha and GR-beta are produced from two separate genes; GR-alpha mediates transactivation exclusively and GR-beta mediates transrepression exclusively, so the two isoforms divide the genomic functions between them
E) GR-beta binds glucocorticoids with higher affinity than GR-alpha and enhances GR-alpha-mediated transcription when co-expressed; elevated GR-beta therefore produces glucocorticoid hypersensitivity rather than resistance
ANSWER: A
Rationale:
GR-alpha (glucocorticoid receptor alpha) and GR-beta (glucocorticoid receptor beta) are generated by alternative splicing of the same NR3C1 gene and differ in their ligand-binding domains. GR-alpha is the principal functional isoform: it binds glucocorticoids and mediates the classical genomic actions (both transactivation and transrepression). GR-beta has an altered ligand-binding domain that does not bind glucocorticoids; rather than mediating glucocorticoid signaling, it acts as a dominant-negative inhibitor of GR-alpha by competing for coactivators and DNA-binding sites. Elevated GR-beta expression in peripheral blood mononuclear cells has been associated with glucocorticoid resistance in asthma and other inflammatory conditions. Distinguishing the ligand-binding functional isoform (GR-alpha) from the non-binding dominant-negative isoform (GR-beta) is foundational to understanding clinical steroid resistance.
Option B: Option B is incorrect because it reverses the two isoforms. GR-alpha is the functional, ligand-binding isoform; GR-beta is the non-binding dominant-negative isoform. The option swaps their roles.
Option C: Option C is incorrect because GR-alpha and GR-beta do not bind glucocorticoids with equal affinity — GR-beta does not bind glucocorticoids at all. The functional difference is in ligand binding and dominant-negative activity, not merely in tissue distribution.
Option D: Option D is incorrect because GR-alpha and GR-beta arise from alternative splicing of a single gene (NR3C1), not from two separate genes. Furthermore, GR-alpha mediates both transactivation and transrepression; the two isoforms do not divide the genomic functions, and GR-beta does not mediate transrepression — it does not bind ligand at all.
Option E: Option E is incorrect because GR-beta does not bind glucocorticoids with higher affinity than GR-alpha, and it does not enhance GR-alpha-mediated transcription. GR-beta acts as a dominant-negative inhibitor, and elevated GR-beta is associated with glucocorticoid resistance, not hypersensitivity. The option inverts both the binding property and the clinical consequence.
8. Glucocorticoid effects can be classified by their time course as genomic or non-genomic. Correctly distinguishing the time scale and the molecular basis of these two categories is foundational. Which of the following statements correctly distinguishes a non-genomic glucocorticoid effect from a genomic one?
A) Both genomic and non-genomic effects require at least 30 to 60 minutes because both depend on transcription and translation; they differ only in which genes are transcribed
B) The non-genomic effect of rapid annexin-A1 (lipocortin-1) externalization, which inhibits phospholipase A2 and reduces arachidonic acid release, requires several hours because annexin-A1 must first be synthesized de novo via GRE-dependent transcription
C) A genomic effect such as GRE-dependent induction of gluconeogenic enzymes occurs within seconds because the glucocorticoid receptor is already present in the cytoplasm and requires no new protein synthesis
D) A non-genomic effect such as rapid externalization of annexin-A1 (lipocortin-1) — which inhibits phospholipase A2 and reduces arachidonic acid availability — occurs within seconds to minutes and is too rapid to be explained by transcription, whereas a genomic effect such as GRE-dependent gene transactivation requires at least 30 to 60 minutes for transcription and translation
E) Non-genomic effects occur only at low physiological glucocorticoid concentrations, while genomic effects occur only at high pharmacological concentrations; the two categories never operate simultaneously in the same cell
ANSWER: D
Rationale:
Genomic and non-genomic glucocorticoid effects are distinguished by time course and molecular basis. Non-genomic effects occur within seconds to minutes — far too rapidly to be explained by gene transcription and translation, which require a minimum of 30 to 60 minutes. A representative non-genomic effect is the rapid externalization of annexin-A1 (lipocortin-1) to the outer cell membrane, where it inhibits phospholipase A2 (PLA2) and reduces arachidonic acid release, limiting substrate for eicosanoid synthesis. This occurs through membrane-associated glucocorticoid receptor signaling (coupled to Src kinase and PI3K), not through new gene transcription. Genomic effects, such as GRE (glucocorticoid response element)-dependent transactivation of gluconeogenic enzyme genes, require transcription and translation and therefore have an onset of at least 30 to 60 minutes. The seconds-to-minutes versus 30-to-60-minutes distinction is the foundational criterion separating the two categories.
Option A: Option A is incorrect because non-genomic effects do not require 30 to 60 minutes and do not depend on transcription and translation. They occur within seconds to minutes precisely because they bypass gene transcription. Only genomic effects require the 30-to-60-minute transcription-translation interval.
Option B: Option B is incorrect because rapid annexin-A1 externalization does not require de novo synthesis via GRE-dependent transcription. The non-genomic effect involves rapid translocation of existing annexin-A1 to the membrane surface within minutes, not new synthesis over hours. De novo synthesis would make the effect genomic and slow, contradicting its observed rapidity.
Option C: Option C is incorrect because GRE-dependent induction of gluconeogenic enzymes is a genomic effect that requires transcription and translation and therefore takes at least 30 to 60 minutes — it does not occur within seconds. The presence of cytoplasmic receptor does not eliminate the requirement for new gene transcription and protein synthesis in genomic signaling.
Option E: Option E is incorrect because non-genomic and genomic effects are distinguished by time course and mechanism, not by an exclusive concentration relationship. Non-genomic effects are particularly prominent at high pharmacological concentrations (as in high-dose IV pulse therapy), and both genomic and non-genomic mechanisms can operate simultaneously in the same cell. The claim that the two categories never operate together is incorrect.
9. A recurring source of confusion in glucocorticoid pharmacology is the difference between a drug's plasma half-life and its biologic duration of action. Using hydrocortisone as the reference example, which of the following correctly distinguishes these two parameters and explains why they differ?
A) The plasma half-life and the biologic duration of action are the same parameter measured by two different methods; for hydrocortisone both are approximately 8 to 12 hours, and any apparent discrepancy reflects assay variability
B) Hydrocortisone has a plasma half-life of approximately 60 to 90 minutes but a biologic duration of action of approximately 8 to 12 hours; the biologic effect outlasts the plasma concentration because glucocorticoid receptor-mediated transcriptional changes persist after plasma drug levels have declined
C) Hydrocortisone has a biologic duration of action of 60 to 90 minutes but a plasma half-life of 8 to 12 hours; the plasma concentration outlasts the biologic effect because the drug is sequestered in plasma protein-bound form long after its receptors have been downregulated
D) The biologic duration of action is always shorter than the plasma half-life for all glucocorticoids because receptor desensitization terminates the effect before the drug is cleared from plasma
E) Hydrocortisone has a plasma half-life and biologic duration that are both approximately 36 to 54 hours, identical to dexamethasone, because all glucocorticoids share the same receptor and therefore the same duration of genomic effect
ANSWER: B
Rationale:
The plasma half-life and the biologic duration of action are distinct parameters. The plasma half-life describes how long the drug persists in measurable plasma concentration; for hydrocortisone this is approximately 60 to 90 minutes. The biologic duration of action describes how long the pharmacological effect lasts; for hydrocortisone this is approximately 8 to 12 hours. The biologic effect outlasts the plasma concentration because glucocorticoids act largely through GR (glucocorticoid receptor)-mediated changes in gene transcription, and these transcriptional changes — and the proteins they produce — persist after plasma drug concentrations have fallen. This dissociation is characteristic of all glucocorticoids and is clinically important: it means once-daily or twice-daily dosing is pharmacologically sufficient even for agents with short plasma half-lives.
Option A: Option A is incorrect because the plasma half-life and biologic duration are not the same parameter, and for hydrocortisone they differ substantially (60 to 90 minutes versus 8 to 12 hours). The discrepancy is real and mechanistically based on persistent transcriptional effects, not assay variability.
Option C: Option C is incorrect because it reverses the two values. Hydrocortisone has a short plasma half-life (60 to 90 minutes) and a longer biologic duration (8 to 12 hours) — not the other way around. The biologic effect outlasts the plasma concentration, not the reverse, and the explanation is persistent genomic effect, not plasma protein sequestration.
Option D: Option D is incorrect because the biologic duration of action is longer than the plasma half-life for glucocorticoids, not shorter. The persistence of genomic transcriptional effects causes the biologic effect to outlast plasma drug levels. Receptor desensitization terminating the effect before clearance does not describe glucocorticoid pharmacology.
Option E: Option E is incorrect because hydrocortisone does not have a plasma half-life and biologic duration of 36 to 54 hours, and it is not identical to dexamethasone. Hydrocortisone's biologic duration is 8 to 12 hours; dexamethasone's is 36 to 54 hours. Different glucocorticoids have different durations of action despite acting through the same receptor, because their pharmacokinetic and receptor-residence properties differ.
10. Prednisone and prednisolone are frequently treated as interchangeable, but they differ in one pharmacologically important respect. Which of the following correctly distinguishes the two and identifies the enzyme that links them?
A) Prednisolone is an inactive prodrug that must be converted to the active compound prednisone by hepatic CYP3A4; in hepatic failure this conversion fails, so prednisone is preferred
B) Prednisone and prednisolone are distinct drugs with different receptor targets; prednisone acts on the mineralocorticoid receptor while prednisolone acts on the glucocorticoid receptor, so they are not interchangeable under any circumstances
C) Prednisone and prednisolone are stereoisomers that interconvert spontaneously in plasma without enzymatic catalysis; neither requires hepatic activation, and hepatic function has no bearing on their interchangeability
D) Prednisolone is the inactive form and prednisone is the active form; prednisolone is converted to prednisone by 11β-HSD2 (11 beta-hydroxysteroid dehydrogenase type 2) in the kidney, and renal failure impairs this activation
E) Prednisone is an inactive prodrug that must be converted to the active compound prednisolone by hepatic 11β-HSD1 (11 beta-hydroxysteroid dehydrogenase type 1); in normal hepatic function this conversion is rapid and nearly complete, making them clinically interchangeable, but in severe hepatic insufficiency prednisolone is preferred to bypass the activation step
ANSWER: E
Rationale:
Prednisone is an inactive prodrug that must be converted to its active form, prednisolone, by 11β-HSD1 (11 beta-hydroxysteroid dehydrogenase type 1) in the liver. In patients with normal hepatic function, this conversion is rapid and nearly complete, which is why prednisone and prednisolone are clinically interchangeable for most purposes. However, in patients with severe hepatic insufficiency, impaired 11β-HSD1 activity can reduce the generation of prednisolone from prednisone, and prednisolone is therefore preferred in this setting to bypass the activation requirement. The key distinction is that prednisone is the prodrug and prednisolone is the active drug, linked by hepatic 11β-HSD1.
Option A: Option A is incorrect because it reverses the prodrug relationship and misidentifies the enzyme. Prednisone (not prednisolone) is the inactive prodrug, and the activating enzyme is 11β-HSD1 (not CYP3A4). The preferred agent in hepatic failure is prednisolone (the active form), not prednisone.
Option B: Option B is incorrect because prednisone and prednisolone do not have different receptor targets and are not active on different receptors. Prednisone is simply the inactive prodrug of prednisolone; once converted, prednisolone acts on the glucocorticoid receptor (with modest mineralocorticoid activity). They are interchangeable when hepatic conversion is intact.
Option C: Option C is incorrect because prednisone and prednisolone are not spontaneously interconverting stereoisomers. Prednisone is enzymatically converted to prednisolone by 11β-HSD1; the conversion requires enzymatic catalysis, and hepatic function does bear on their interchangeability in severe liver disease.
Option D: Option D is incorrect because it reverses the active and inactive forms and misidentifies both the enzyme and the organ. Prednisone is the inactive prodrug and prednisolone is the active form; the activating enzyme is hepatic 11β-HSD1, not renal 11β-HSD2. 11β-HSD2 inactivates cortisol to cortisone in mineralocorticoid target tissues and is not the activating enzyme for prednisone.
11. Dexamethasone and methylprednisolone are both used as systemic glucocorticoids, but they differ markedly in potency, mineralocorticoid activity, and duration. Which of the following correctly distinguishes dexamethasone from methylprednisolone across these properties?
A) Dexamethasone and methylprednisolone have identical anti-inflammatory potency (approximately 5-fold that of hydrocortisone) and identical biologic durations of action; they differ only in that dexamethasone is given orally and methylprednisolone only intravenously
B) Methylprednisolone has higher anti-inflammatory potency than dexamethasone (30-fold versus 5-fold that of hydrocortisone) and a longer biologic duration of action (36 to 54 hours versus 18 to 36 hours), making methylprednisolone the agent of choice for cerebral edema
C) Dexamethasone has an anti-inflammatory potency of approximately 25 to 30 times that of hydrocortisone, essentially no mineralocorticoid activity, and a long biologic duration of action of 36 to 54 hours; methylprednisolone has a potency of approximately 5 times that of hydrocortisone, negligible mineralocorticoid activity, and a shorter biologic duration of 18 to 36 hours
D) Dexamethasone has significant mineralocorticoid activity that makes it unsuitable for cerebral edema, whereas methylprednisolone has high mineralocorticoid activity that makes it the preferred agent when sodium retention is desirable
E) Dexamethasone and methylprednisolone both have a biologic duration of action of 8 to 12 hours, identical to hydrocortisone, and both must be dosed every 8 hours to maintain anti-inflammatory effect
ANSWER: C
Rationale:
Dexamethasone and methylprednisolone differ substantially across the key pharmacological parameters. Dexamethasone has the highest anti-inflammatory potency among routinely used systemic glucocorticoids — approximately 25 to 30 times that of hydrocortisone — essentially no mineralocorticoid activity, and the longest biologic duration of action at 36 to 54 hours. Methylprednisolone has an anti-inflammatory potency of approximately 5 times that of hydrocortisone, negligible mineralocorticoid activity, and a biologic duration of 18 to 36 hours. Both agents have minimal sodium-retaining activity, but dexamethasone's much higher potency and longer duration make it the preferred agent for cerebral edema, while methylprednisolone is favored for IV pulse therapy. Distinguishing their potency and duration is foundational to rational agent selection.
Option A: Option A is incorrect because dexamethasone and methylprednisolone do not have identical potency or duration. Dexamethasone is approximately 25 to 30 times as potent as hydrocortisone with a 36-to-54-hour duration, whereas methylprednisolone is approximately 5 times as potent with an 18-to-36-hour duration. The route of administration is not the only difference.
Option B: Option B is incorrect because it reverses the potency and duration values. Dexamethasone (not methylprednisolone) has the higher potency (25 to 30-fold) and the longer duration (36 to 54 hours). Dexamethasone, not methylprednisolone, is the agent of choice for cerebral edema.
Option D: Option D is incorrect because dexamethasone has essentially no mineralocorticoid activity — that is one of the properties that makes it preferred for cerebral edema. Methylprednisolone also has negligible mineralocorticoid activity. Neither agent has high sodium-retaining activity, and sodium retention is never a desirable property in the management of cerebral edema.
Option E: Option E is incorrect because neither dexamethasone nor methylprednisolone has a biologic duration of 8 to 12 hours — that is the duration of hydrocortisone. Dexamethasone's duration is 36 to 54 hours and methylprednisolone's is 18 to 36 hours; neither requires every-8-hour dosing to sustain anti-inflammatory effect.
12. Methylprednisolone and prednisolone have similar anti-inflammatory potencies and biologic durations, yet methylprednisolone is specifically preferred in certain patients. Which of the following correctly identifies the property that distinguishes them and the clinical situation in which that distinction matters?
A) Methylprednisolone has moderate mineralocorticoid activity (approximately 0.8-fold that of hydrocortisone) while prednisolone has none, so prednisolone is preferred when sodium retention must be avoided
B) Methylprednisolone has negligible mineralocorticoid activity, whereas prednisolone retains moderate mineralocorticoid activity (approximately 0.8-fold that of hydrocortisone); methylprednisolone is therefore preferred when sodium retention must be minimized, such as in patients with hypertension, edema, or heart failure
C) Methylprednisolone and prednisolone have identical mineralocorticoid activity, so the choice between them is determined entirely by cost and route of administration, not by sodium-retaining potential
D) Prednisolone has negligible mineralocorticoid activity while methylprednisolone has high mineralocorticoid activity equivalent to that of hydrocortisone, so prednisolone is preferred when sodium retention must be avoided
E) Methylprednisolone has approximately 25 to 30 times the anti-inflammatory potency of prednisolone and no mineralocorticoid activity; the large potency difference, not mineralocorticoid activity, is what distinguishes the two agents clinically
ANSWER: B
Rationale:
Methylprednisolone and prednisolone have comparable anti-inflammatory potencies (approximately 5-fold and 4-fold that of hydrocortisone, respectively) and similar biologic durations (18 to 36 hours), but they differ in mineralocorticoid activity. Methylprednisolone has negligible mineralocorticoid (sodium-retaining) activity, whereas prednisolone retains moderate mineralocorticoid activity of approximately 0.8-fold that of hydrocortisone. This difference makes methylprednisolone the preferred agent when minimizing sodium retention is clinically important — for example, in patients with hypertension, peripheral edema, or heart failure, in whom the sodium-retaining activity of prednisolone could worsen volume status. Distinguishing these two otherwise-similar agents by their mineralocorticoid activity is the foundational point.
Option A: Option A is incorrect because it reverses the mineralocorticoid activities. Methylprednisolone has negligible mineralocorticoid activity, while prednisolone retains moderate (approximately 0.8-fold) mineralocorticoid activity. Methylprednisolone, not prednisolone, is the agent preferred when sodium retention must be avoided.
Option C: Option C is incorrect because methylprednisolone and prednisolone do not have identical mineralocorticoid activity. Methylprednisolone has negligible mineralocorticoid activity, whereas prednisolone has moderate activity (0.8-fold). The choice between them is influenced by this sodium-retaining difference, not solely by cost and route.
Option D: Option D is incorrect because it reverses the mineralocorticoid activities. Methylprednisolone has negligible mineralocorticoid activity; it does not have high activity equivalent to hydrocortisone. Prednisolone has the moderate mineralocorticoid activity. The preferred agent for avoiding sodium retention is methylprednisolone, not prednisolone.
Option E: Option E is incorrect because methylprednisolone is not 25 to 30 times as potent as prednisolone — their anti-inflammatory potencies are similar (approximately 5-fold versus 4-fold that of hydrocortisone). The 25-to-30-fold potency figure belongs to dexamethasone. The distinguishing property between methylprednisolone and prednisolone is mineralocorticoid activity, not a large potency difference.
13. Budesonide achieves a separation between local anti-inflammatory effect and systemic adverse effects that distinguishes it from prednisone. Which of the following correctly identifies the pharmacokinetic property responsible for this separation and distinguishes local from systemic exposure?
A) Budesonide is not absorbed at all from the gut, so it produces local anti-inflammatory effect with zero systemic exposure; this complete lack of absorption distinguishes it from prednisone, which is fully absorbed
B) Budesonide undergoes minimal first-pass metabolism, achieving approximately 90% systemic bioavailability; its steroid-sparing reputation derives entirely from its lower intrinsic receptor affinity rather than from any pharmacokinetic property
C) Budesonide selectively binds an intestinal-specific glucocorticoid receptor subtype not present in liver, bone, or muscle, producing local effect without systemic adverse effects through receptor selectivity rather than pharmacokinetics
D) Budesonide achieves high local concentrations at the gut mucosa through targeted release, then undergoes approximately 85 to 90% first-pass hepatic metabolism to inactive metabolites, limiting systemic bioavailability to approximately 10 to 15%; this pharmacokinetic profile produces local anti-inflammatory effect with substantially reduced systemic exposure compared with prednisone
E) Budesonide is converted by hepatic first-pass metabolism into a more potent active metabolite, increasing its systemic glucocorticoid effect above that of prednisone while paradoxically reducing local mucosal anti-inflammatory activity
ANSWER: D
Rationale:
Budesonide's separation between local and systemic effect is a pharmacokinetic phenomenon. Given in targeted-release oral formulations, budesonide achieves high local concentrations at the gut mucosa, providing potent local anti-inflammatory effect. After absorption, it undergoes approximately 85 to 90% first-pass hepatic metabolism to inactive metabolites (16-alpha-hydroxyprednisolone and 6-beta-hydroxybudesonide), limiting its systemic bioavailability to approximately 10 to 15%. The result is robust local anti-inflammatory transrepression in the bowel mucosa with substantially less systemic transactivation-mediated adverse effect (including less HPA suppression) than would accompany an equipotent dose of prednisone. The distinction between high local concentration and low systemic bioavailability — driven by first-pass metabolism — is the foundational concept.
Option A: Option A is incorrect because budesonide is absorbed from the gut; it does not achieve local effect through zero absorption. After absorption, it is extensively inactivated by first-pass hepatic metabolism, which is what limits systemic exposure — not a complete failure of absorption.
Option B: Option B is incorrect because budesonide undergoes extensive (not minimal) first-pass metabolism, with systemic bioavailability of only approximately 10 to 15% (not 90%). Its steroid-sparing profile derives from this high first-pass inactivation, a pharmacokinetic property, not from lower intrinsic receptor affinity — budesonide actually has high topical glucocorticoid potency.
Option C: Option C is incorrect because there is no intestinal-specific glucocorticoid receptor subtype. Budesonide acts on the same ubiquitously expressed GR-alpha as other glucocorticoids; its local-versus-systemic separation is pharmacokinetic (first-pass metabolism), not a consequence of receptor selectivity.
Option E: Option E is incorrect because budesonide's first-pass metabolism produces inactive metabolites, not a more potent active metabolite. First-pass metabolism reduces systemic glucocorticoid exposure rather than increasing it, and budesonide's local mucosal anti-inflammatory activity is preserved, not reduced. The option inverts the direction of the metabolic effect.
14. Cortisol is carried in plasma by two proteins with opposite binding characteristics. Correctly distinguishing the affinity and capacity of these two carriers is essential to understanding why free cortisol rises disproportionately at high concentrations. Which of the following correctly characterizes the two carriers?
A) CBG (corticosteroid-binding globulin, also called transcortin) is a high-affinity, low-capacity carrier that becomes saturated at plasma cortisol concentrations of approximately 25 to 30 micrograms per deciliter; albumin is a low-affinity, high-capacity carrier that accepts cortisol once CBG is saturated
B) CBG is a low-affinity, high-capacity carrier that never saturates at clinically achievable concentrations; albumin is a high-affinity, low-capacity carrier that saturates first and determines the free fraction at physiological concentrations
C) CBG and albumin both have high affinity and high capacity for cortisol, so the free fraction remains constant at approximately 5 to 10% across all plasma concentrations and total cortisol always predicts free cortisol accurately
D) Albumin is the primary high-affinity carrier responsible for approximately 70 to 75% of cortisol binding, while CBG is a minor low-affinity carrier responsible for only 15 to 20%; saturation of albumin at high concentrations increases the free fraction
E) CBG binds cortisol covalently and therefore cannot be saturated or displaced; the free fraction is determined entirely by the rate of hepatic cortisol synthesis rather than by any property of the binding proteins
ANSWER: A
Rationale:
Cortisol is carried by two plasma proteins with opposite binding characteristics. CBG (corticosteroid-binding globulin, also called transcortin) is a high-affinity, low-capacity carrier that binds approximately 70 to 75% of circulating cortisol but becomes saturated at plasma cortisol concentrations of approximately 25 to 30 micrograms per deciliter. Albumin is a low-affinity, high-capacity carrier that binds approximately 15 to 20% of cortisol and accepts additional cortisol once CBG is saturated. Because albumin binds with lower affinity, a larger proportion of albumin-bound cortisol is in equilibrium with the free fraction; consequently, once CBG is saturated, the free (biologically active) fraction rises disproportionately with each additional increment in total plasma cortisol. Distinguishing the high-affinity/low-capacity carrier (CBG) from the low-affinity/high-capacity carrier (albumin) is the foundational concept.
Option B: Option B is incorrect because it reverses the binding characteristics. CBG is the high-affinity, low-capacity carrier that saturates at approximately 25 to 30 micrograms per deciliter, while albumin is the low-affinity, high-capacity carrier. CBG does saturate at clinically achievable concentrations — that saturation is precisely what drives the disproportionate rise in free cortisol.
Option C: Option C is incorrect because the free fraction is not constant across all plasma concentrations. At physiological concentrations the free fraction is approximately 5 to 10%, but once CBG saturates at pharmacological or stress-level concentrations, the free fraction rises disproportionately. CBG and albumin do not both have high affinity and high capacity — they have opposite profiles, and total cortisol does not reliably predict free cortisol at high concentrations.
Option D: Option D is incorrect because it reverses the roles of the two carriers. CBG (not albumin) is the high-affinity carrier responsible for approximately 70 to 75% of binding; albumin is the low-affinity, high-capacity carrier responsible for approximately 15 to 20%. The disproportionate rise in free fraction follows saturation of CBG, not albumin.
Option E: Option E is incorrect because CBG binds cortisol non-covalently and reversibly — it can be saturated, and it is saturated at approximately 25 to 30 micrograms per deciliter. The free fraction is determined by the binding properties and saturation state of CBG and albumin, not solely by the rate of hepatic cortisol synthesis.
15. Glucocorticoids are metabolized primarily by CYP3A4, so drugs that alter CYP3A4 activity change glucocorticoid plasma concentrations in opposite directions. Which of the following correctly distinguishes the effect of a CYP3A4 inducer from that of a CYP3A4 inhibitor on glucocorticoid levels and clinical consequence?
A) CYP3A4 inducers such as rifampin increase glucocorticoid plasma concentrations and can cause iatrogenic Cushing syndrome, while CYP3A4 inhibitors such as ketoconazole decrease glucocorticoid concentrations and can precipitate adrenal insufficiency
B) Both CYP3A4 inducers and CYP3A4 inhibitors decrease glucocorticoid plasma concentrations; they differ only in the speed of onset, with inducers acting within hours and inhibitors acting over weeks
C) CYP3A4 inducers and inhibitors have no clinically significant effect on glucocorticoid concentrations because glucocorticoids are eliminated primarily by renal excretion of unchanged drug rather than by hepatic metabolism
D) Both CYP3A4 inducers and CYP3A4 inhibitors increase glucocorticoid plasma concentrations; inducers do so by increasing absorption and inhibitors by reducing clearance, so both raise the risk of iatrogenic Cushing syndrome
E) CYP3A4 inducers such as rifampin, phenytoin, and carbamazepine accelerate glucocorticoid metabolism and can reduce plasma concentrations by 50 to 75%, risking loss of therapeutic effect or adrenal crisis in dependent patients; CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir reduce glucocorticoid metabolism and increase plasma concentrations, risking iatrogenic Cushing syndrome
ANSWER: E
Rationale:
Glucocorticoids are eliminated primarily by CYP3A4 (cytochrome P450 3A4)-mediated hepatic metabolism, so drugs that modulate CYP3A4 change glucocorticoid concentrations in opposite directions. CYP3A4 inducers — rifampin, phenytoin, carbamazepine, and phenobarbital — increase the enzyme's metabolic capacity, accelerating glucocorticoid clearance and reducing plasma concentrations by 50 to 75%; in glucocorticoid-dependent patients this risks loss of therapeutic effect or precipitation of adrenal crisis. CYP3A4 inhibitors — ketoconazole, itraconazole, ritonavir and other protease inhibitors, and clarithromycin — reduce metabolism and increase glucocorticoid plasma concentrations, risking iatrogenic Cushing syndrome even at standard doses (a recognized hazard with inhaled corticosteroids in patients on ritonavir-boosted regimens). The key discrimination is directional: inducers lower levels, inhibitors raise them.
Option A: Option A is incorrect because it reverses the directional effects. CYP3A4 inducers (rifampin) decrease glucocorticoid concentrations and risk adrenal insufficiency; CYP3A4 inhibitors (ketoconazole) increase concentrations and risk iatrogenic Cushing syndrome. The option swaps the two effects.
Option B: Option B is incorrect because CYP3A4 inducers and inhibitors do not both decrease glucocorticoid concentrations. Inducers decrease concentrations by accelerating metabolism; inhibitors increase concentrations by slowing metabolism. They act in opposite directions, not merely at different speeds.
Option C: Option C is incorrect because glucocorticoids are eliminated primarily by hepatic CYP3A4 metabolism, not by renal excretion of unchanged drug. CYP3A4 inducers and inhibitors therefore do have clinically significant, and opposite, effects on glucocorticoid concentrations.
Option D: Option D is incorrect because CYP3A4 inducers and inhibitors do not both increase glucocorticoid concentrations. Inducers reduce concentrations by accelerating clearance; only inhibitors raise concentrations. Inducers do not increase absorption, and they lower — not raise — the risk of Cushing syndrome while raising the risk of adrenal insufficiency.
16. Assessment of HPA axis recovery after glucocorticoid therapy relies on morning plasma cortisol thresholds that must be applied correctly. Which of the following correctly distinguishes the three interpretive zones of the morning cortisol value and the appropriate action for each?
A) A morning cortisol greater than 3 micrograms per deciliter confirms full HPA recovery; a value between 1 and 3 indicates partial recovery; a value below 1 requires lifelong replacement, and dynamic testing is never indicated
B) A morning cortisol greater than 50 micrograms per deciliter indicates adequate recovery; values between 18 and 50 require dynamic testing; values below 18 indicate persistent suppression requiring permanent therapy
C) Morning cortisol cannot be interpreted in zones; only a single cutoff of 10 micrograms per deciliter exists, above which the axis is normal and below which it is suppressed, with no role for intermediate testing
D) A morning cortisol greater than 18 micrograms per deciliter (approximately 500 nmol per liter) indicates adequate HPA recovery and low adrenal crisis risk; a value below 3 micrograms per deciliter indicates persistent severe suppression; intermediate values require dynamic testing, most practically the low-dose short Synacthen test (LDSST) with 1 microgram of synthetic ACTH
E) A morning cortisol greater than 18 micrograms per deciliter indicates persistent suppression requiring continued therapy, while a value below 3 indicates full recovery; the relationship between cortisol value and axis function is inverse because of feedback regulation
ANSWER: D
Rationale:
Morning plasma cortisol, measured at 8:00 to 9:00 AM when endogenous drive is at its circadian peak, is interpreted in three zones. A value greater than 18 micrograms per deciliter (approximately 500 nmol per liter) indicates adequate HPA axis recovery and low risk of adrenal crisis, generally permitting glucocorticoid discontinuation without further testing. A value below 3 micrograms per deciliter indicates persistent severe suppression and continued glucocorticoid dependence. Intermediate values (between 3 and 18) require dynamic testing to characterize the stress-response capacity of the axis; the most practical test in routine use is the low-dose short Synacthen test (LDSST), in which 1 microgram of synthetic ACTH (tetracosactide) is given intravenously and cortisol is measured at 30 minutes, with a peak response greater than 18 micrograms per deciliter considered normal. Correctly distinguishing the three zones — adequate, suppressed, and indeterminate-needing-testing — is the foundational concept.
Option A: Option A is incorrect because the threshold for adequate recovery is greater than 18 micrograms per deciliter, not greater than 3. A value of 3 micrograms per deciliter is the lower threshold indicating severe suppression, not a marker of full recovery. Dynamic testing is indicated for intermediate values, contrary to the claim that it is never used.
Option B: Option B is incorrect because the adequate-recovery threshold is greater than 18 micrograms per deciliter, not greater than 50. A value of 18 micrograms per deciliter already indicates adequate recovery; values above this do not require dynamic testing, and values modestly below 18 do not automatically indicate a need for permanent therapy — they indicate a need for dynamic testing.
Option C: Option C is incorrect because morning cortisol is interpreted in three zones, not by a single 10-microgram-per-deciliter cutoff. The established thresholds are greater than 18 (adequate) and below 3 (suppressed), with an intermediate zone requiring dynamic testing. A single 10-microgram-per-deciliter cutoff with no intermediate testing does not reflect clinical practice.
Option E: Option E is incorrect because the relationship between morning cortisol and HPA axis function is direct, not inverse. A higher morning cortisol (greater than 18) indicates better axis function and adequate recovery; a lower value (below 3) indicates suppression. The option inverts the interpretation, which would dangerously misclassify recovered and suppressed patients.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.